← All trials
NCT05066620
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Dec 31, 2024
- Completion date
- Jan 31, 2025
- First posted
- Oct 4, 2021
- Last posted
- Oct 4, 2021
- Enrollment
- 1504
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou UniversityLead sponsor
- University of New South WalesCollaborator
- University of New South WalesOverall official - principal investigator
- Guangzhou UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.